Drug intelligence / Profile preview

4-MPTC

Development stage: Preclinical
Modality: Small Molecules

Overview

4-MPTC is a small molecule modulator of calcium signaling that specifically targets the Stim2-dependent calcium entry pathway. Identified through small molecule screening, it induces a significant release of calcium from the endoplasmic reticulum (ER) and inhibits store-operated calcium entry (SOCE). Preclinical research indicates that 4-MPTC reduces the proliferation and migration of MDA-MB-468 triple-negative breast cancer cells, suggesting its potential as a therapeutic agent or sensitizer in oncology by disrupting calcium homeostasis in malignant cells.

Targets

ORAI3 (Calcium release-activated calcium channel protein 3)STIM1 (Stromal interaction molecule 1)STIM2 (Stromal interaction molecule 2)

Beyond the preview

Go deeper on 4-MPTC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-MPTC.

Explore the full profile